213 related articles for article (PubMed ID: 27504556)
1. AParadigm Shift: The New Novel Oral Anticoagulation Agents.
Saeed W; Burke JF; Mirrani G; Sirinivasa M; Nabi U; Hayat U; Khan Z; Sardar MR
J Coll Physicians Surg Pak; 2016 Jul; 26(7):611-9. PubMed ID: 27504556
[TBL] [Abstract][Full Text] [Related]
2. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
Hirano T; Kaneko H; Mishina S; Wang F; Morita S
J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
4. Which oral anticoagulant for atrial fibrillation.
Med Lett Drugs Ther; 2016 Apr; 58(1492):45-6. PubMed ID: 27049507
[No Abstract] [Full Text] [Related]
5. Novel anticoagulants for stroke prevention in patients with atrial fibrillation.
Jalota A; Scarabelli TM; Saravolatz L; Bakhsh MU; Agrawal P; Jalota R; Chen-Scarabelli C; Fuster V; Halperin J
Cardiovasc Drugs Ther; 2014 Jun; 28(3):247-62. PubMed ID: 24842559
[TBL] [Abstract][Full Text] [Related]
6. Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation.
Nakamura A; Kuroda J; Ago T; Hata J; Matsuo R; Arakawa S; Kuwashiro T; Yasaka M; Okada Y; Kitazono T; Kamouchi M;
Cerebrovasc Dis; 2016; 42(3-4):196-204. PubMed ID: 27111222
[TBL] [Abstract][Full Text] [Related]
7. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial.
Singer DE; Hellkamp AS; Yuan Z; Lokhnygina Y; Patel MR; Piccini JP; Hankey GJ; Breithardt G; Halperin JL; Becker RC; Hacke W; Nessel CC; Mahaffey KW; Fox KA; Califf RM;
J Am Heart Assoc; 2015 Mar; 4(3):e001349. PubMed ID: 25736441
[TBL] [Abstract][Full Text] [Related]
8. Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation.
Williams BA; Evans MA; Honushefsky AM; Berger PB
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29025746
[TBL] [Abstract][Full Text] [Related]
9. Direct oral anticoagulants: unique properties and practical approaches to management.
Barnes GD; Kurtz B
Heart; 2016 Oct; 102(20):1620-6. PubMed ID: 27402803
[TBL] [Abstract][Full Text] [Related]
10. Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.
Deitelzweig S
Cardiovasc Ther; 2014 Apr; 32(2):74-81. PubMed ID: 24119252
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry.
Turk UO; Tuncer E; Alioglu E; Yuksel K; Pekel N; Ozpelit E; Vuran O; Tengiz I
Cardiol J; 2015; 22(5):567-75. PubMed ID: 26100825
[TBL] [Abstract][Full Text] [Related]
13. Beyond warfarin: a patient-centered approach to selecting novel oral anticoagulants for stroke prevention in atrial fibrillation.
Patel KK; Mehdirad AA; Lim MJ; Ferreira SW; Mikolajczak PC; Stolker JM
J Hosp Med; 2014 Jun; 9(6):400-6. PubMed ID: 24715600
[TBL] [Abstract][Full Text] [Related]
14. New oral anticoagulants: their role in stroke prevention in high-risk patients with atrial fibrillation.
Ferns SJ; Naccarelli GV
Med Clin North Am; 2015 Jul; 99(4):759-80. PubMed ID: 26042881
[TBL] [Abstract][Full Text] [Related]
15. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
[TBL] [Abstract][Full Text] [Related]
16. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
Mahaffey KW; Hellkamp AS; Patel MR; Hannan KL; Schwabe K; Nessel CC; Berkowitz SD; Halperin JL; Hankey GJ; Becker RC; Piccini JP; Breithardt G; Hacke W; Singer DE; Califf RM; Fox KA
Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):470-8. PubMed ID: 23759472
[TBL] [Abstract][Full Text] [Related]
17. [New treatments for stroke and thromboembolism prevention in atrial fibrillation].
Shiyovich A; Khalameizer V; Katz A
Harefuah; 2014 Jan; 153(1):32-8, 64. PubMed ID: 24605405
[TBL] [Abstract][Full Text] [Related]
18. Personalizing oral anticoagulant treatment in patients with atrial fibrillation.
Capranzano P; Miccichè E; D'Urso L; Privitera F; Tamburino C
Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):959-73. PubMed ID: 23957907
[TBL] [Abstract][Full Text] [Related]
19. Trials of novel oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
Halperin JL; Dorian P
Curr Cardiol Rev; 2014 Nov; 10(4):297-302. PubMed ID: 24821657
[TBL] [Abstract][Full Text] [Related]
20. NOAC or Warfarin for Atrial Fibrillation: Does Time in Therapeutic Range Matter?
Merinopoulos I; Venables P; Chalmers I; Vassiliou V
Recent Adv Cardiovasc Drug Discov; 2015; 10(1):60-4. PubMed ID: 26365270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
